✨ Free AI Report
Orphazyme ApS: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Orphazyme ApS
Company Research

Orphazyme ApS: Business Overview, Financials & Competitive Analysis

Orphazyme ApS scores 3/10 on the AskCyborg Cyborg Score (Challenged). Post-restructuring shell company with negligible revenue, limited assets, and strategic challenges despite historical heat-shock protein platform leadership. Orphazyme executed a near-total asset sale in May 2022, divesting its core arimoclomol program and severely constraining its operational capacity. Current revenue is minimal ($5.1M estimated for 2026), workforce is extremely reduced, and.

What is Orphazyme ApS's industry? Orphazyme ApS (orphazyme.com) operates in Orphan Drugs. AskCyborg classifies Orphazyme ApS under Orphan Drugs in its company registry.

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Founded in 2009 and publicly listed in 2017, the company pioneered heat-shock protein response technolo...

3/ 10Challenged

Cyborg Score thesis

Post-restructuring shell company with negligible revenue, limited assets, and strategic challenges despite historical heat-shock...

Read the full analyst-debate transcript →
Industry Orphan Drugs
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 12, 2026
AI-Verified Research
30+ Page Report

Get the Latest Orphazyme ApS Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Orphazyme ApS

AskCyborg analysts argue the bull and bear cases for Orphazyme ApS across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Orphazyme ApS OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Orphazyme ApS Overview

Pro stress-test →

Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Founded in 2009 and publicly listed in 2017, the company pioneered heat-shock protein response technology to treat rare neurodegenerative diseases.

Strategic Profile

Pro stress-test →

In May 2022, substantially all assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S (Zevra A/S). The company currently operates as a shell biopharmaceutical entity with minimal commercial revenue and a substantially reduced operational footprint.

Competitive Landscape

Pro stress-test →

Orphazyme operates in orphan/rare disease treatment development but has largely exited active competition following its 2022 asset sale. Arimoclomol is now developed by Zevra (formerly KemPharm Denmark). The rare neurodegeneration space includes competitors developing treatments for similar conditions, but Orphazyme itself maintains minimal pipeline presence.

Industry Context

Orphazyme ApS operates in Orphan Drugs.

Key facts

Founded: 2009 · Headquarters: Copenhagen, Denmark · Employees: 14 · Revenue: $5.1M (2026) · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Orphazyme ApS.

  • Asset divestiture in May 2022 transferred arimoclomol program and core operations to Zevra (formerly KemPharm Denmark), leaving Orphazyme with minimal operational assets and severely constraining future revenue generation capacity.
  • Revenue was $5.1 million in 2026, reflecting a severely diminished operational footprint and absence of commercialized products following the strategic restructuring and asset sale.
+1 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2022Asset sale to Zevra/KemPharm Denmark including arimoclomol development program and core business activities
  • 2022Workforce reduced by approximately 50% and commercial operations closed in Germany, UK, and US
  • +1 moreTrack every material event for Orphazyme ApS as it happens. Explore monitoring →
Get alerted when Orphazyme ApS has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

MitobridgeDevelops mitochondrial therapeutics for rare neurodegenerative diseases including Niemann-Pick disease type C→Reata PharmaceuticalsBiopharmaceutical company developing therapies for rare and orphan diseases including neurodegeneration→Akcea TherapeuticsFocuses on rare genetic diseases and lysosomal storage disorders with neurodegeneration→Cayuga PharmaceuticalsDeveloping therapies for rare neurological and lysosomal storage diseases→

Compare Orphazyme ApS with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Orphazyme ApS operates in Orphan Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Orphan Drugs research →
NEW · MCP server

Ask your AI assistant about Orphazyme ApS

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Orphazyme ApS and its top competitor on Cyborg Score”
“What did Orphazyme ApS do this quarter?”
“Is Orphazyme ApS a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Orphazyme ApS do?+
Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Founded in 2009 and publicly listed in 2017, the company pioneered heat-shock protein response technolo...
What is Orphazyme ApS's Cyborg Score?+
Orphazyme ApS has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Orphazyme ApS's main competitors?+
Named competitors include Mitobridge, Reata Pharmaceuticals, Akcea Therapeutics, Cayuga Pharmaceuticals. The full competitive landscape is in the AskCyborg report.
How can I get the full Orphazyme ApS research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Orphazyme ApS research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Orphazyme ApS over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.